Therefore, we systematically and comprehensively performed the present meta‐analysis to integrate the results of these published studies, aiming to investigate the diagnostic efficiency of cfDNA as a biomarker for KRAS mutations determination compared with the "gold‐standard" tumor tissues and to evaluate the predictive and prognostic value of cfDNA KRAS mutations in CRC patients. Here, KRAS is linked to colorectal carcinoma.